Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma.

Q2 Medicine BMC Clinical Pathology Pub Date : 2017-04-04 eCollection Date: 2017-01-01 DOI:10.1186/s12907-017-0046-z

Mohamed Reda El Ochi, Mohamed Oukabli, Elarbi Bouaiti, Hafsa Chahdi, Adil Boudhas, Mohamed Allaoui, Ahmed Ameur, Mohamed Abbar, Abderrahmane Al Bouzidi

{"title":"Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma.","authors":"Mohamed Reda El Ochi, Mohamed Oukabli, Elarbi Bouaiti, Hafsa Chahdi, Adil Boudhas, Mohamed Allaoui, Ahmed Ameur, Mohamed Abbar, Abderrahmane Al Bouzidi","doi":"10.1186/s12907-017-0046-z","DOIUrl":null,"url":null,"abstract":"Background: Urothelial bladder carcinoma (UBC) is one of the most prevalent cancers in men worldwide. Human epidermal growth factor receptor 2 (HER2) expression has been detected in a wide range of urothelial carcinoma. Despite many reports in the literature, the prognostic significance of this overexpression remains unclear. The aim of this study was to assess the expression of HER2 in urothelial bladder carcinomas and its association with clinical and pathological parameters.Methods: 103 cases of UBC were diagnosed in our department between January 2014 and December 2015. The tumor specimens obtained by transurethral resection or cystectomy were evaluated by immunohistochemistry using HER2 antibody.Results: HER2 protein overexpression was present in 11.7% of cases and associated with tumor grade (p = 0.003) and pathological stage (p = 0.015). In multivariate analysis, HER2 overexpression was associated only with tumor grade (P = 0.04).Conclusion: HER2 protein overexpression is noted in patients with high grade cancer. This expression may select patients for anti HER2 targeted therapy. Future larger and prospective studies will verify the frequency of HER2 alteration and the role of HER2 in the aggressive behavior.","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"17 ","pages":"3"},"PeriodicalIF":0.0000,"publicationDate":"2017-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-017-0046-z","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Clinical Pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s12907-017-0046-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 14

Abstract

Background: Urothelial bladder carcinoma (UBC) is one of the most prevalent cancers in men worldwide. Human epidermal growth factor receptor 2 (HER2) expression has been detected in a wide range of urothelial carcinoma. Despite many reports in the literature, the prognostic significance of this overexpression remains unclear. The aim of this study was to assess the expression of HER2 in urothelial bladder carcinomas and its association with clinical and pathological parameters.

Methods: 103 cases of UBC were diagnosed in our department between January 2014 and December 2015. The tumor specimens obtained by transurethral resection or cystectomy were evaluated by immunohistochemistry using HER2 antibody.

Results: HER2 protein overexpression was present in 11.7% of cases and associated with tumor grade (p = 0.003) and pathological stage (p = 0.015). In multivariate analysis, HER2 overexpression was associated only with tumor grade (P = 0.04).

Conclusion: HER2 protein overexpression is noted in patients with high grade cancer. This expression may select patients for anti HER2 targeted therapy. Future larger and prospective studies will verify the frequency of HER2 alteration and the role of HER2 in the aggressive behavior.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

人表皮生长因子受体2在膀胱尿路上皮癌中的表达。

背景:尿路上皮性膀胱癌(UBC)是世界范围内男性最常见的癌症之一。人表皮生长因子受体2 (HER2)在尿路上皮癌中广泛表达。尽管文献中有许多报道，但这种过表达的预后意义尚不清楚。本研究的目的是评估HER2在尿路上皮性膀胱癌中的表达及其与临床和病理参数的关系。方法:2014年1月至2015年12月在我科诊断的UBC患者103例。经尿道切除或膀胱切除术获得的肿瘤标本采用免疫组化HER2抗体进行评估。结果:11.7%的病例存在HER2蛋白过表达，并与肿瘤分级(p = 0.003)和病理分期(p = 0.015)相关。在多变量分析中，HER2过表达仅与肿瘤分级相关(P = 0.04)。结论:HER2蛋白在高级别肿瘤患者中存在过表达。这种表达可以选择抗HER2靶向治疗的患者。未来更大规模的前瞻性研究将验证HER2改变的频率以及HER2在攻击行为中的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

BMC Clinical Pathology Medicine-Pathology and Forensic Medicine

CiteScore

3.30

自引率

0.00%

发文量

期刊介绍： BMC Clinical Pathology is an open access journal publishing original peer-reviewed research articles in all aspects of histopathology, haematology, clinical biochemistry, and medical microbiology (including virology, parasitology, and infection control). BMC Clinical Pathology (ISSN 1472-6890) is indexed/tracked/covered by PubMed, CAS, EMBASE, Scopus and Google Scholar.